Tohutoro APA (7th ed.)

Inês Pereira Amaral, Joana Antunes, Ivânia Soares, Madalena Pupo Correia, & Paulo Filipe. (2023). Deucravacitinib, a TYK2 inhibitor, safety in psoriasis and psoriatic arthritis: What should a dermatologist know? Wiley.

Tohutoru Kātū Chicago (17th ed.)

Inês Pereira Amaral, Joana Antunes, Ivânia Soares, Madalena Pupo Correia, me Paulo Filipe. Deucravacitinib, a TYK2 Inhibitor, Safety in Psoriasis and Psoriatic Arthritis: What Should a Dermatologist Know? Wiley, 2023.

Tohutoro MLA (9th ed.)

Inês Pereira Amaral, et al. Deucravacitinib, a TYK2 Inhibitor, Safety in Psoriasis and Psoriatic Arthritis: What Should a Dermatologist Know? Wiley, 2023.